No differentiation for Roche's degrader
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Ideaya’s first pivotal catalyst looms
Darovasertib data are promised for the last week of March.
Sensei finds Faeth
The company buys in a PI3Kα and mTOR combo.
MAT2A inhibition gets another endorsement
Gilead opting against IDE397 is still good news for Ideaya.
